Loading
companiesCompany
Nektar Therapeutics
Nektar is a San Francisco biotechnology company whose polymer conjugation chemistry underlies several approved drugs and whose engineered interleukin-2, bempegaldesleukin, failed in phase 3 with nivolumab in 2022.
Also called: Nektar
Overview
Nektar Therapeutics, listed on Nasdaq, built its business on PEGylation and polymer conjugate chemistry licensed into products such as pegfilgrastim-type molecules and movantik. Its own oncology bet, bempegaldesleukin (NKTR-214), a PEGylated interleukin-2 designed to favour effector T cells, was developed with Bristol Myers Squibb in a large phase 3 programme with nivolumab that reported negative results in melanoma, renal cell carcinoma and bladder cancer in 2022, after which the programme was closed. OnCo records it as a registry sponsor of phase 3 cancer trials.
Headquarters
San Francisco, CA, US
Scorecard
All companies#446of 1244 companies, score 7
- modalities +2
- registry trials +8
- failures -3
0 approved, 0 in phase 3, 0 earlier, 0 targets, 16 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
NegativeEngineered cytokine (PEGylated IL-2)
Bempegaldesleukin was a re-engineered interleukin-2 meant to be a safer version of a famous old immunotherapy. It added nothing to nivolumab in three phase 3 trials.
Similar pages
- TargetIL2RB
Shares Bempegaldesleukin, Renal cell carcinoma, Melanoma.
- TrialA Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
Shares Bempegaldesleukin, Bristol Myers Squibb, Melanoma.
- TrialA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Shares Bristol Myers Squibb, Renal cell carcinoma.
- TrialA Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance
Shares Bristol Myers Squibb, Renal cell carcinoma.
- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal
Shares Bristol Myers Squibb, Renal cell carcinoma.
- TrialA Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed
Shares Bristol Myers Squibb, Melanoma.
- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- TrialA Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Shares Bristol Myers Squibb, Melanoma.
cancers
fronts
drugs
NegativeEngineered cytokine (PEGylated IL-2)
companies
trials
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence